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La variabilité des taux plasmatiques de voriconazole mesurés par de 
nouvelles méthodes de chromatographie liquide à haute performance et 
de bioassay 
Le voriconazole (VRC) est un antifongique à large spectre de la classe des triazoles 
avec une pharmacocinétique non linéaire. L'utilité de la mesure de ses taux 
sanguins pour optimaliser le traitement est débattue. Les méthodes de dosage 
actuellement disponibles par chromatographie liquide à haute performance (HPLC) 
et par bioassay sont techniquement complexes. Elles prennent du temps ou ont un 
intervalle analytique étroit. Les objectifs de cette étude étaient de développer de 
nouvelles méthodes d'analyse simple et d'évaluer la variabilité des taux sanguins de 
voriconazole chez des patients avec une infection mycotique invasive. Pour le 
dosage par HPLC, nous avons utilisé une précipitation par acétonitrile, une 
séparation par "reverse-phase" et une détection par rayons UV . Une souche mutée 
de Candida albicans hypersensible pour le voriconazole a été utilisée pour le 
bioassay. Cette souche a été construite par délétion des gènes pour les transporteurs 
multidrogues (cdr JLJ/cdr JLJ, cdr2L1/cdr2L1, fluJLJ/flulLJ et mdr JLJ/mdr JLJ) et la sous-
unité A de la calcineurin (cnaL1/cnaL1). 
L'exactitude des principales valeurs de l'intra- /interrun sur des concentrations de 
voriconazole allant de 0.25 à 16 mg/l était de 93.7 % ± 5.0% / 96.5 % ± 2.4 % 
pour HPLC, et de 94.9 % ± 6.1 % / 94. 7% ± 3.3 % pour le bioassay. 
Les coefficients de variation des principales valeurs intra- / interrun étaient de 5 .2 % 
± 1.5 % I 5.4 % ± 0.9 % pour HPLC, et de 6.5 % ± 2.5 % I 4.0 % ± 1.6 % pour 
bioassay. 
Le coefficient de concordance entre l'HPLC et le bioassay était de 0.96. 
Des mesures séquentielles sur 10 patients avec une infection mycotique invasive ont 
été réalisées. Elles ont montré, pour une courbe temps / concentration, que l'aire 
sous la courbe (AUC) était sujette à d'importantes variations inter- et 
intraindividuelles. Par exemple, pour le premier jour de traitement la valeur 
moyenne était de 43.9 mg·h/l (sur un intervalle de 12.9 à 71.1) et pour le dernier 
jour, de 27.4 mg·h/l (sur un intervalle de 2.9 à 93.1). Durant le traitement, l' AUC a 
diminué pour 5 patients, augmenté pour 3 et elle est restée stable pour 2. Une 
encéphalopathie toxique, probablement en relation avec l'augmentation de l'aire 
sous la courbe du voriconazole (de 71.1 à 93.1 mg·h/l), a été observée. L'AUC du 
VRC a diminué de 12.9 à 2.9 mg·h/l chez un patient présentant des signes 
persistants d'aspergillose. Ces observations préliminaires suggèrent qu'un sur ou 
sous dosage de voriconazole entraînant une variation des taux sanguins pourrait 
avoir un impact clinique. Ces méthodes simples d'HPLC et de bioassay offrent de 
nouvelles perspectives pour le suivi des patients traités par voriconazole. 
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Voriconazole (VRC) is a broad-spectrum antifungal triazole with nonlinear pharmacokinetics. The utility of 
measurement of voriconazole bloocl levels for optimizing therapy is a matter of clebate. Available high-
performance Iiquicl chromatography (HPLC) and bioassay methods are technically complex, time-consuming, 
or have a narrow analytical range. Objectives of the present stucly were to develop new, simple analytical 
methods and to assess variability of voriconazole bloocl levels in patients with invasive mycoses. Acetonitrile 
precipitation, reverse-phase separation, and UV cletection were used for HPLC. A voriconazole-hypersuscep-
tible Candida albicans mutant lacking nrnlticlrug elfiux transporters (edrl Â/cdrl Â, cdr2Â/cdr2Â, f/ul A/jlul Â, 
and mdrl Â/mdrl Â) ancl calcineurin subunit A (cnaÂ/cnaÂ) was usecl for bioassay. Mean intra-/interrun 
accuracies over the VRC concentration range from 0.25 to 16 mg/liter were 93.7% ± 5.0%/96.5% ± 2.4% 
(HPLC) ancl 94.9% ± 6.1%/94.7% ± 3.3% (bioassay). Mean intra-/interrun coefficients of variation were 5.2% ± 
1.5%/5.4% ± 0.9% and 6.5% ± 2.5%/4.0% ± 1.6% for HPLC and bioassay, respectively. The coefficient of 
concordance between HPLC and bioassay was 0.96. Sequential measurements in 10 patients with invasive 
mycoses showecl important inter- ancl intrainclividual variations of estimatecl voriconazole area uncler the 
concentration-time curve (AUC): meclian, 43.9 mg· h/liter (range, 12.9 to 71.1) on the first and 27.4 mg· h/liter 
(range, 2.9 to 93.1) on the las! day of therapy. During therapy, AUC decreasecl in five patients, increased in 
three, and remainecl unchangecl in two. A toxic encephalopathy probably relatecl to the increase of the VRC 
AUC (from 71.1 to 93.l mg · h/liter) was observecl. The VRC AUC decreasecl (from 12.9 to 2.9 mg · h/liter) in 
a patient with persistent signs of invasive aspergillosis. These preliminary observations suggest that voricon-
azole over- or unclerexposure resulting from variability of bloocl levels might have clinical implications. Simple 
HPLC ancl bioassay methocls offer new tools for monitoring voriconazole therapy. 
Voriconazole (VRC) is a new treatment option for aspergil-
losis, candidiasis, other emerging or refractory mycoses, and 
persistent fever during neutropenia (1, 4, 6, 8, 12, :15, 22, 25, 
36). Combinations of VRC with other antifungal agents are 
being investigated for use with severe infections (3, 21). A 
correlation between in vitro MIC of VRC and response to 
antifungal therapy has been described previously (26). The 
VRC area under the concentration-time curve (AUC)/MIC 
ratio is the pharmacokinetic/-dynamic parameter which best 
predicts success in experimental candidiasis (2). Nonlinear 
phannacokinetics, genetic polymorphism of the cytochrome 
P450 enzyme CYP2Cl9, changes in volume of distribution, 
drug interactions, hepatic dysfonction, and age may modify 
VRC pharmacokinetics (10, 13, 14, 16, 28). lnterindividual 
variability of VRC blood levels has been reported previously, 
but it is unclear whether intraindividual variations also occur 
during therapy (10). VRC blood levels of <0.5 mg/liter (MIC90 
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for Candida and Aspc1gil/11s spp.) have been observed in 20% 
of patients with invasive aspergillosis (10). VRC trough blood 
concentrations of <0.25 mg/liter have been reported for chil-
dren (35). Denning et al. clescribed treatment failures in pa-
tients with VRC plasma concentrations of <0.25 mg/liter (6). 
VRC blood levels as high as 15 mg/liter were observed for 
subjects with liver toxicity or a "poor metabolizer" CYP2Cl9 
genotype (5-7, 10, 14, 27). Whether measurement of VRC 
blood levels may optimize therapy in individual patients is a 
matter of debate (7). 
Reported high-performance liquicl chromatography (HPLC) 
methods are characterized by complex extraction, long analyt-
ical time, or limited analytical range (11, 23, 24, 34). A bioassay 
methocl using Candida kefyr ATCC 46764 (VRC MIC, 0.015 
mg/liter) has been valiclatecl over a range of 0.8 to 3.6 mg/liter 
(24). Clinical observations suggest that quantification of VRC 
blood levels between 0.25 and 15 mg/liter is neecled. Azole-
hypersusceptible C. ulbicuns mutants constructed by targetecl 
cleletion of genes encoding multiclrug effiux transporters and 
calcineurin offer interesting tools for clevelopment ofbioassays 
(19, 20, 31 ). The objectives of this stucly were to clevelop simple 
HPLC and bioassay methocls with a clinically relevant analyt-
ical range and to assess the variability of VRC blood levels by 
sequential measurements in patients with invasive mycoses. 
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(Part of the study was presented at the 44th Interscience 
Conference on Antimicrobial Agents and Chemotherapy, 30 
October to 2 November 2004, Washington, DC.) 
MATEIUALS AND METHODS 
HPLC. (i) Sam pie preparation. Fivc hundred microliters of plasma and 500 µl 
of acetonitrile (Merck, Darmstadt, Germany) were vortexed/mixed (10 s), stored 
at 4'C (W min), and centrifuged at 17,900 X g (5 min). The supernatant (500 pJ) 
was transferred into an Eppendorftube and evaporated under nitrogen stream (1 
h) (nitrogen dryer; bioMérieux, Marcy l'Etoile, France). The dry residue was 
reconstituted in 200 µI of ultrapure water (Direct-Q water system; Millipore, 
Bedford, MA). 
(ii) System. The HPLC system (Hitachi Instruments, lchige, Hitachinaka, 
Japan) consisted of an L-2200 Peltier autosampler, an L-2100 gradient pump 
(with low-pressure mixing), and an L-2450 diode array detector. The results were 
analyzed using EZChrorn Elite software, version 3. 1 (Hitachi Instruments, 
Tokyo, Japan). 
(iii) Conditions, Samples were maintained at 4'C in the autosampler prior to 
injection, and the column temperature was maintained at 35'C, Fifty-microliter 
samples were injected and separated using a reverse-phase C 18 column (Nucleo-
sil 300-5, C 18, 15 cm by 4.6 mm; Macherey-Nagel, Oensingen, Switzerland) with 
a universal security guard cartridge (Macherey-Nagel, Oensingen, Switzerland), 
an isocratic gradient of 50% (vol/vol) methanol (Merck, Dietikon, Switzerland) 
in 0.01 M sodium acetate buffer, pH 5.0 (Merck, Dietikon, Switzerland), and a 
flow rate of the mobile phase of 1.0 ml/min. The eluent was monitored at a 
255-nm wavelength (deuterium lamp; Hamamatsu Photonics, Toyooka, Japan) 
and absorbance measured in arbitrary units. 
(iv) Analysis. Each analytical run included one blank, eight standards, and four 
quality control samples (see paragraph i in "Validation of HPLC and bioassay" 
section). Al! samples were analyzed in duplicate. The amount of VRC was 
calculated by an external standard mcthod based on peak areas (see paragraph 
iii in "Validation of HPLC and hioassay" section). 
llioassay. (i) Strnins, C. albica11s mutant DSY2621 was constructed by targeted 
deletions of genes encoding membrane efflux transporters (cdrl!::.::hisG/cdrlt:.:: 
hisG, cdr2!::.::hisG/cdr2t:.::hisG, Jiu! !::.::hisG/jl11J !::.::hisG, and mdrl t:.::hisG/ 
mdrl !::.::hisG) and calcineurin su bu nit A (cna!::.::hisG/cna!::.::hisG-URA3-hisG) 
(VRC MIC, 0.008 mg/liter) (31). C. a/bicans ATCC 95020 (VRC MIC, 0.015 
mg/liter) and C. kcfyr BI 1501, a clinicat isolate from the collection of the micro-
biology laboratory of our hospital (VRC MIC, 0.015 mg/liter), were also usecl. 
Strains were maintained at 4'C on Sabouraud dextrose agar plates (Difco Lah-
oratories, Base!, Switzerland). 
(ii) Inoculum. A single CFU of the test strain was grown overnight under 
agitation (214 rpm) at a temperature of 35'C in 2 ml of yeast extract-peptone-
dextrose medium (10 g/liter !facto peptone (Difco Laboratories, Basci, Switzer-
land], 5 g/\iter ycast extract [Difco Laboratories, Base!, Switzerland], and 20 
g/liter glucose (Fluka, Steinheim, Switzerland]). An inoculum of 1.5 X 107 
CFU/ml was prepared by diluting the overnight culture with 0.9% NaCI to an 
optical density of 0.4 arbitrary units of absorbance at a wavelength of 540 nm 
(Novaspec II; Pharmacia Biotech, Cambridge, England). The viable counts of 
the inoculum were determined by suhcultures on Sabouraud dextrose agar 
plates. 
(iii) Medium and aga1· plate. A broth medium (412.5 ml) containing 25 g/liter 
agar (Becton Dickinson, Sparks, MD) and 8 g/liter ofyeast nitrogen base (Becton 
Dickinson, Sparks, MD) was autoclaved and then allowed to equilibrate at a 
temperature of 50'C. Fifty milliliters of a 20% glucose aqueous solution was 
added (Sigma-Aldrich Chemie, Steinheim, Germany). A buffer solution (12.8 
ml) (7.15 g KH2P0.1 [Sigma-Aldrich Chemie, Steinheim, Genuany] anù 50 g 
Na2HP04 · 2H20 [Merck, Darmstadt, Germany] diluted in 500 ml of bidistil\ed 
water with a final pH of 5.5), 115 ml of broth medium, and 2.6 ml of inoculum 
wcrc mixed at a tcmperature of 50'C. The final volume of 130.4 ml was poured 
into a square glass plate (220 by 220 mm). The agar was allowed to solidify at 
room temperature. Thereafter, 16 round wells (diameter, 4 mm; capacity, 25 µl) 
were eut using a sterile cork borer over a standard tcmplate. Each well was filled 
with 25 µ!of plasma, which was allowed to diffuse through the agar at 4'C for 2 h. 
The plate was then incubated at 35'C for 14 h. 
(iv) Analysis. Each analytical run includeù the following plasma samples in 
duplicate: one blank, eight standards, and four quality controls. Growth inhibi-
tion around wells was quantified by measuring the horizontal, the vertical, and 
the two diagonal diameters lo the nearest 0.1 mm with a Vernier caliper. The 
amount of VRC was calculated by an external standard method (see paragraph 
iii in "Validation of HPLC and hioassay" section). 
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Validation of HPLC and bioassny. HPLC and bioassay were internally vali-
dated over a concentration range of 0.25 to 16 mg/liter according ta the inter-
national recommendations for analytical method validation (9, 32). 
(i) Spikcd plasma samples. Citrateù plasma from healthy donors was kindly 
supplied by the blood transfusion service of our hospital. A batch of spiked 
human plasma samples was prepared from an aqueous stock solution containing 
1 mg/liter of VRC. VRC pure substance was kindly supplied by Plizer Central 
Research (Sandwich, United Kingdom). Eight standards (i.e., samples used to 
calculate a regression equation) were obtained by serial dilutions: 0.19, 0.39, 0.78, 
1.56, 3.12, 6.25, 12.5, and 25 mg/liter. The four quality control samples (i.e., used 
for back calculation of VRC values by the regression eguation) contained 0.25, 
l, 4, and 16 mg/liter. Aliquots of each concentration were prepared for HPLC 
(500 µ!)and bioassay (60 µ.!)and frozen at -SO'C. Spiked plasma samplcs from 
a unique batch were used for the entire validation procedure. 
(ii) Limits of cletection and quantification. The limit of detection (LOD) was 
delincd as the lowest VRC concentration that couic! be diffcrentiated rcliably 
from background noise (mean of 12 different background noise measurements :!: 
3 standard deviations for HPLC) or coulù be recognized as a delimited zone of 
growth inhibition (for bioassay). The limit of quantification (LOQ) was defined 
as the lowest amount of VRC thnt could be quantified in a plasma sample with 
:!:20% accuracy and precision (9, 32). 
(iii) Stanclarcl cm·ves. Curves consisting of eight points (0.2 to 25 mg/liter) 
were calculated by linear regression (best fit obtained by exploring different 
weighting factors when plotting peak areas measured by HPLC against VRC 
concentrations) or by quadratic regrcssion (best lit obtainecl by plotting diamc-
ters of growth inhibition measured hy bioassay against VRC concentrations). 
(fr) Recovery of VRC from plasma. The absolute rccovery of VRC from 
plasma (biological matrix) was calculated for the four quality control samples as 
follows: measured concentration in plasma/measured concentration in water X 
100. To i•ssess the efficiency of VRC extraction [rom plasma, a 50-µl volume of 
water spiked with VRC was injected into the 1-IPLC (equaling 100% recovery); 
percent recovcry of VRC from extracted plasma was calculated according to the 
formula given above. 
(v) Influence of the anticoagulant on VRC quantification. The percentages of 
measured/nominal VRC values in quality control samples were compared in 
plasma containing citrate, heparin, or EDTA and in serum. Citrated standard 
plasma samples were used for the calibration curve. 
(vi) Quantification of VRC over lime under clifferent storngc conditions. QuaI-
ity controls were tested for stability of VRC over time (percent ùeviation of 
measured from initial values) (a) in plasma at 4 and 2l'C (7 days), (h) in plasma 
al -SO'C (12 months), and (c) in plasma during four freeze-thaw cycles. Stability 
was also mcasured in whole blood from a patient treated with VRC at 4 and 21 'C 
(7 days). 
(vii) Accuracy and precision, lntra- and internm accuracy (measurcd value/ 
nominal value X 100) and prccision [(coefficient of variation) = (standard 
ùeviation/mean of measureù values X 100)] were assessed for the four quality 
controls with six duplicate measurements within the same experiment or in six 
experiments (each with duplicate measurements) perfonned on different days, 
respectively. 
(viii) Selcctivity. To assess the selectivity of the HPLC method for VRC, the 
fol\owing antifungals, antibiotics, antivirals, and immunosuppressants were tested 
with VRC: (a) amphotericin B, caspofungin, 5-Ilucytosine, llueonazole, and itra-
conazole; (h) amoxicillin-clavulanic acid, piperacillin-tazobactam, cefepime, ceftazi-
dime, ccftriaxone, imipenem, meropenem, teîcoplanin, vancomycin, clîndamycin, 
clarithromycin, ciprofloxacin, levofloxacin, metronidazole, trimethoprim, amikacin, 
gentamiciu, and rifampiu; (c) amprennvir, efavirenz, indinavir, lopinavir, uelfinavir, 
nevirapine, saquinavir, and ritonavir; and ( d) cyclosporine A and tacrolimus. 
(ix) Conco1·dnnce between HPLC and bioassay. The agreement between VRC 
levels measmed by HPLC and bioassay in plasma samples from patients treated 
with VRC was analyzed by a method proposed by Lin (17). Measmements by 
HPLC and bioassay were performed by two different investigators who were 
blindcd of the results obtainecl with the othcr mcthod. The coefficient of con-
cordance was calculated using the following parameters: 111 and 11.2, means of 
values measured by HPLC and bioassay; "•and crz, standard deviations of values 
measured by HPLC and bioassay; location shift (u), (µ 1 - µ 2)/\l(<r1 - cr2); scale 
shift (v), rr1/<T2; precision (r), coefficient of correlation; congruence (A), [(v + l!v + 
µ 2)/2r 1; concordance, r x A. 
Mcasurements of VRC blood levels in patients with invasive mycoses. Inpa-
tients receiving VRC therapy in the ward of the Infections Diseases Service over 
a 9-month period were studied after provicling written informed consent. The 
study protocol was approved by the lnstitutional Ethical Committee. VRC load-
ing and maintenance doses fol!owed manufacturer's recommendations. Clinical 
data on demographics, diagnosis of fungal infection ( according to EORTC/MSG 
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TABLE 1. Intra- and interrun validation of the HPLC method and the bioassay"·d 
HPLC Bioassay 
Nominal VRC Intranm (11 = 6) lnterrun (11 = 6) 
concn(s) lntrarun (n = 6) Interrun (11 = 6) 
(mg/liter) Accuracy" Coellkient of Accuracy Coellicient of Accuracy Coellkient of Accuracy CoeOicient of 
(%) variationc (%) (%) variation (%) (%) variation (%) (%) variation (%) 
0.25 100.7 ± 6.4 6.4 98.9 ± 4.2 5.1 89.0 ± 4.1 5.0 90.9 ± 3.6 4.2 
1 89.8 ± 3.5 3.9 93.2 ± 5.6 6.3 99.2 ± 10.2 10.3 96.3 ± 5.8 6.1 
4 90.1 ± 6.0 6.6 96.2 ± 5.9 5.9 96.6 ± 5.0 5.2 97.8 ± 2.1 2.2 
16 94.3 ± 3.6 3.9 97.5 ± 5.0 4.3 94.7 ± 5.2 5.5 93.9 ± 1.7 3.6 
Ail 93.7 ::':: 5.0 5.2 ± 1.5 96.5 ± 2.4 5.4 ± 0.9 94.9 ± 6.1 6.5 :!: 2.5 94.7 ± 3.3 4.0 ± 1.6 
"The bioassay method used the C. albicans mutant lacking four multidrug c!llux transportcrs (cdrl Mcdrl Il, cdr2Mcdr2è., jlul!J./jhil Il, and 111drl è./111drl Il) and the 
calcineurin subunit A (cna!l/cna!l). 
h The accuracy was calculated as follows: measured concentration/nominal concentration X 100. 
c The cocOicicnt of variation was calculatcd as follows: starnlard dcviation of mcasurcd conccntration/mcan mcasmed concentration X 100. 
11 Mean values :±: standard deviations are shown. 
criteria), response to therapy (complete or partial clinical/raùiological resolution 
or persistent signs of infection), comedications, and adverse events (according to 
National Cancer lnstitute grading criteria) were prospcctively collected. VRC 
hlood levels were measurcd on days 2, 7, and 14 of antifungal therapy. Two 
millilitcrs of citratcd blood was drawn just before and 2, 4, 6, and 12 h after VRC 
administration. VRC levels were measured by HPLC as described above. Aver-
age exposure to VRC was assessed by the estimated AUC over one dosing 
interval (0 to 12 h) calculated by the linear trapezoidal rule during increase and 
the log trapezoidal rule during decay (29). VRC peak concentrations in serum 
(Cm"x), trough concentrations, and estimated AUC values were analyzcd by 
descriptive statistics. 
REsm;rs 
HPLC. A plasma peak overlapping with that of VRC at a 
retention time of 8 min was observed using a recently reported 
HPLC method (24). The effect was independent from the type 
of organic matrix and occurred in plasma containing citrate, 
heparin, or EDTA and in serum. To eliminate this interfer-
ence, we modified the experimental conditions by using a dif-
ferent mobile phase (50/50 [vol/vol] methanol and sodium ac-
etate) and a shorter column (C18, 150 by 4.6 mm, 5 \Lill). The 
run timc was significantly shorter (12 min), and the chromato-
gram showed a VRC peak free of interferences after a reten-
tion time of 7.4 min regardless of the type of biological matrix 
(plasma with diffcrent anticoagulants or scrum). 
For the standard cutve, a lincar regression with a 1/x2 
weighting factor was used (sum of the relative errors by back 
calculation of the VRC concentrations in standards, 2.9%; 
range of relative errors, 0.4 to 5.9%; constant variability of 
relative errors over the analytical range, 0.125 to 25 mg/liter). 
The mean cutve parameters were as follows: a = 287,048 :':: 
27,801; h = -4,816 :±: 7,372; r2 = 0.0997 :::':: 0.002. The LOD 
and LOQ of VRC were 0.04 and 0.125 mg/liter, respectively. 
The absolute VRC recovery was 102% :':: 6%. The influence of 
the biological matrix on VRC quantification was studied. The 
mean percent ratios of measured/expected VRC values in 
plasma containing citrate, heparin, or EDTA and in serum 
were 93.7% :::':: 5.0%, 87% :::':: l.6%, 89.1 % :':: 5.7%, and 
91.9% :::':: 1.9%, rcspectively. The quantifications ovcr time of 
VRC in stored plasma (measured values/initial values X 100) 
were 95% :':: 4% and 94% :':: 3% at 4 and 21°C, respectively, 
over 7 days, 98% ± 9% at -80°C over 12 months, and 95% :':: 
7% after four freeze-thaw cycles. The ratios (measured values/ 
initial values X 100) in whole blood drawn from patients 
treated with VRC and stored over 4 days were 92% :':: 4% at 
4°C and 95% ± 6% at 21°C. 
Table l summarizes the results of intrarun and interrun 
validations over the 0.25- to 16-mg/liter concentration range. 
The mean intrarun accuracy was 93.7% :::':: 5.0%, and the mean 
coellicient of variation was 5.2% :::':: 1.5%. The mean interrun 
accuracy was 96.5% :':: 2.4%, and the mean coefficient of vari-
ation was 5.4% :':: 0.9%. 
To assess the selectivity of the HPLC method, the retention 
times of the commonly used antifungals (n = 5), antibiotics 
(n = 18), antivirals (n = 8), and immunosuppressive drugs 
(11 = 2) listed in Materials and Methods were studied. The 
antiretroviral agents indinavir and amprenavir had retention 
times overlapping with that of VRC, leading to potential in-
terferences with calculation of the VRC concentrations. No 
interference was observed between VRC and the remaining 
drugs. 
Bioassay. VRC bioassays using the azole-hypersusceptible 
C. albicans mutant (cdrl /J./cdrl !:., cdr2/J./cdr2/J., flul /J.!flul/J., 
mdrl /J.lmdrl !:., and cna /J./cna /J.), the reference strain C. albi-
cans ATCC 95020, and the clinical isola te C. kej)1r Bl1501 were 
compared. The zones of growth inhibition of the standard 
cmve obtained with the hypersusceptible C. albicans mutant 
were well delimited and ranged between 17 and 52 mm over 
the 0.2- to 25-mg/liter VRC concentration analytical range. 
Those obtained with C. albicans ATCC 95020 and C. kefyr 
B11501 ranged between 21 and 39 mm and between 23 and 39 
mm, respectively. The LOD and LOQ of the methods using the 
azole-hypersusceptible C. albicans mutant were 0.1 mg/liter 
and 0.2 mg/liter, respectively, and those with C. albicans ATCC 
95020 or C. kefyr Bll5(Jl were 0.39 mg/liter and 0.5 mg/liter, 
respectively. With the hypersusceptible mutant, excellent stan-
dard curve reproducibility was obtained (mean :±:: standard 
deviation): b0 = -1.92 :':: 0.42, b 1 = 0.04 :':: 0.02, b2 = 0.0007 :':: 
0.0003, and r2 = 0.998 :':: 0.035. The influence of the biological 
matrix on VRC quantification was studied. The absolute VRC 
recove1y was 99% :':: 0.5%. The mean percent ratios of mea-
sured/nominal VRC values in plasma containing citrate, hep-
arin, or EDTA and in serum were 97.6% :::':: 3.6%, 95.4% :::':: 
1.4%, 95.4% :::':: .l.4%, and 106.3% :':: 3.7%, respectively. The 
quantifications over time of VRC in stored plasma (measured 
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FIG. 1. Scatter plot of plasma VRC levels measured by HPLC and 
bioassay using the C. a!bicans mutant (cdrl !J./cdrl !J., cdr2/:;./cdr2/J., 
fiuJD./jlu!!J., mdrl!J./mdrlD., and cna/:;./cnaD.). The line of congruence 
does not deviate from 1. The coefficient of concordance is 0.96. 
values/initial values X 100) were 99% :t:: 3% and 99% :t:: 3% at 
4 and 21°C, respectively, over 7 days, 99% :t:: 5% at -80°C over 
12 months, and 104% :t:: 4% after four freeze-thaw cycles. The 
ratios (measured values/initial values X 100) in whole blood 
drawn from patients treated with VRC and stored over 4 days 
were 99% :t:: l % at 4°C and 99% ± 0.5% at 21°C. 
The intra-/interrun accuracy (mean, 94.9% :t:: 6.1 %/94.7% :t:: 
3.3%) and precision (mean coefflcients of variation, 6.5% :t:: 
2.5%/4.0% :t:: 1.6%) were well within the recommended vali-
dation limits (accuracy, 85% to 115%, and precision, ±15%) 
(Table 1) (9, 32). 
Concordance between HPLC and bioassay. The comparison 
of the VRC levels measured in 58 clinical plasma samples by 
HPLC and bioassay methods handled by different laboratory 
technicians is shown in Fig. 1. The correlation coefficient was 
0.97 (P < 0.001), and the coefücient of concordance calculated 
according to the method reporte cl by Lin ( 17) was 0.96 (u 
[location shift], 0.007; v [scale shift], 1.283; A [congruence], 
0.99). 
Measurements ofVRC bloocl levels in patients with invasive 
mycoses. Ten Caucasian adult patients were studied (Table 2). 
None had underlying hepatic or renal disease. During the 
study period, VRC dosing schedules remained unchanged. 
VRC blood levels were measured over 7 days of therapy in 
five patients and over 14 days in the remaining five. In seven 
cases, the study ended at discharge from the hospital. In three 
cases, VRC therapy was discontinued after invasive mycosis 
was ruled out (one case), because of a serious adverse event 
(one case), or because of persistent signs of infection requiring 
a switch to a salvage regimen (one case). 
The median Cmax values were 6 mg/liter (range, 2.7 to 6.4) 
on the first day and 3.8 (range, 0.3 to 8.2) on the last day of 
study. The median VRC trough levels were 3 (range, 0.3 to 5.6) 
and 1.2 (range, 0.2 to 7.4), respectively. Average exposure was 
expressed by estimated AUC based on measurements of VRC 
blood levels at three to tlve time points. The median estimated 
VRC AUC value decreased over the study period from 43.9 
mg· h/liter (range, 12.9 to 71.1) to 27.4 mg· h/liter (range, 2.9 
ANT!MICROB. AGENTS CHEMOTHER. 
to 93.1). In five patients, the AUC value decreased (19.9%, 
38.3%, 52.9%, 40.9%, and 77.5% ). One patient was treated 
with VRC intravenously (i.v.), two orally, and two had an 
intravenous-to-oral switch with identical VRC daily doses; two 
patients received concomitant medication with esomeprazole 
and one with imatinib. In three cases, the VRC AUC increased 
(30.6%, 30.9%, and 107.1 % ). Two patients were treated with 
VRC i.v., and one had an intravenous-to-oral switch with no 
change of the VRC daily dose; one patient received esome-
prazole comedication. The VRC AUC remained unchanged in 
two cases ( decreased 5.8% and 9.9% ): one patient was treated 
with VRC orally, and one had an intravenous-to-oral switch 
with the same VRC daily dose. 
Figure 2 shows the course of the estimated VRC AUC 
values during the study period in the 10 patients (Fig. 2A) and 
three individual VRC concentration-time curves (Fig. 2B to 
D). A leukemic patient with proven pulmona1y aspergillosis 
and increasing VRC exposure (at day 2, C1110x was 6.4 mg/liter, 
trough was 5.6 mg/liter, and AUC was 71.1 mg · h/liter; at day 
7, Cmax was 8.2 mg/liter, trough was 7 mg/liter, and AUC was 
93.1 mg · h/liter) under 200 mg orally twice daily developed a 
toxic encephalopathy (confusion, agitation, and hallucinations; 
grade 3 according to NCI classification) and a mild cholestasis 
( alkaline phosphatase three times the upper normal value) 
(Fig. 2B). This adverse event was probably related to high 
VRC blood levels and promptly resolved after interruption of 
therapy. The comedication with esomeprazole may have inter-
acted with VRC metabolism and contributed to the increase of 
VRC exposure. Rechallenge with lower VRC doses (150 mg 
twice daily) was well tolerated. A persistence of signs of prob-
able pulmonary aspergillosis (persistent fever and inflamma-
TABLE 2. Characteristics of Hl patients treated with VRC 
Characteristic 
No. of 
patients with 
characteristic 
Gender (male/female )" ............................................................................... 812 
Underlying conditions 
Acute leukemia/neutropenia after 
myeloablative chemotherapy .......................................................... 8 
None .......................................................................................................... 2 
VRC therapy 
Indications 
Invasive aspergillosis ........................................................................... 7 
Proven/probable ............................................................................... 4/3 
Pulmonary/rhinocere bral/dissem inated ......................................... 5/ l/l 
Possible pulmonary invasive mycosis ................................................ 2 
Persistent fever during neutropenia .................................................. 1 
Settings 
First-line therapy ................................................................................. 4 
Salvage therapy (failure of/intolerance to 
previous antifungal therapy) .......................................................... 4 (2/2) 
lntravenous-to-oral switch after therapy 
with another antifungal agent ........................................................ 2 
Initial route of administration (i.v./oral),, ............................................ 8/2 
lntravenous-to-oral switch during VRC therapy ............................. 4 
Response of infection to antifungal therapy on 
day 14 (complete response/partial 
response/persistcnce of infection) ................................................. 2/6/2 
Adverse event leading to discontinnation of therapy ......................... 1 
"The meùian patient age was 62 years (range, 28 to 64 years), and the median 
patient weight was 69 kg (range, 50 to 98 kg). 
"The rnedian dose, given twice daily, was 4 mg/kg of body weight (range, 2.5 
to 4.6 mg/kg). 
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tory syndrome, radiological progression of the initial focus, and 
documentation of a new contralateral pulmonary lesion) was 
observed during the neutropenic period in a leukemic patient 
receiving 200 mg orally twice daily. A drop in VRC blood levels 
was documented (at day 7, cmm was 1.9 mg/liter, trough was 
0.5 mg/liter, and AUCwas 12.9 mg· h/liter; at day 14, Cmnx was 
0.3 mg/liter, trough was 0.2 mg/liter, and AUC was 2.9 mg · 
h/liter) (Fig. 2C). No cause for the decrease of VRC exposure 
was iclentified: the dose had remained unchanged, no comedi-
cation interacting with VRC metabolism had been added, and 
drug compliance was appropriate. A clinical and radiological 
resolution of the infection was obtained after increase of the 
VRC dose to 300 mg orally twice daily. In another leukemic 
neutropenic patient, persistent signs of probable pulmonary 
aspergillosis (persistent fever, increasing inflammatory syn-
drome, and radiological progression of multiple pulmona1y 
lesions) were observed. With a VRC dose of 300 mg orally 
twice daily, VRC Cmax and trough levels at the time of assess-
ment of persistence of infection were 4.3 and 2.6 mg/liter, 
respectively (AUC had remained unchanged, i.e., 43 mg · h/li-
ter on the first day and 40.5 mg · h/liter on the last day of 
therapy). In this patient, therapy was switched to a salvage 
regimen with liposomal amphotericin B and a complete reso-
lution of infection was obtained. Figure 2D shows stable con-
centration-time curves from a leukemic patient with an un-
eventful clinical course. 
ëi 6 
> Cl> 
...J 
"C 4 0 
0 
ëii 
(.) 
ci:: 2 
> 
0 
0 
C10 
::J 8 
0, 
s 
6 ëi 
> Cl> 
...J 
"O 4 0 
0 
ëii 
(.) 2 ci:: 
> 
0 
0 
D 10 
::J 8 
'ai 
s 
ëi 6 
> Cl> 
...J 
"C 4 0 
0 
ëii 
(.) 2 ci:: 
> 
0 
0 
4 8 
Time after VRC Dose (h) 
Il Day 7 } AAUC-77.5% 
A Day 14 
4 8 
Time after VRC Dose (h) 
1111 Day 2 } ti.AUC -9.9% 
A Day7 
4 8 12 
Time after VRC Dose (h) 
12 
12 
DISCUSSION 
Reported HPLC methods for measurement of VRC blood 
levels are technically complex and/or time-consuming (e.g., 
extraction procedure of >4 h and/or run time of >30 min) (11, 
23, 24, 34). With a recently described method using organic 
phase extraction, we have observed a peak interfering with the 
VRC quantification (24). The reported C. kej)ir ATCC 46764 
bioassay has a limited analytical range (0.8 to 3.6 mg/liter) (24). 
The present study reports the development of new, simple 
HPLC and bioassay methods with an analytical performance 
meeting clinical requirements. 
Plasma VRC extraction by acetonitrile precipitation fol-
lowed by evaporation under nitrogen stream and reverse-phase 
FIG. 2. (A) Courses of estimated VRC AUC in 10 patients. (B to 
D) Individual VRC concentration-lime curves. (B) Patientwith proven 
pulmonary aspergillosis, toxic encephalopathy, and mild cholestasis. 
Increasing VRC blood levels were observed (è.AUC + 30.9%) despite 
an unchangecl VRC dose (200 mg orally twice daily; a switch from i.v. 
to oral treatment had occurrecl). During the entire study period, the 
patient receivecl esomeprazole. This serious neurological adverse event 
was probably related to VRC overclosing and completely resolved after 
stop of VRC therapy. Rechallenge with lower VRC closes (150 mg 
orally twice claily) was well toleratecl. (C) Patient with persistent signs 
of probable pulmonary aspergillosis. Decreasing VRC exposure was 
documentecl (è.AUC - 77.5%) clespite an unchanged VRC close (200 
mg orally t\vice daily) and absence of comedication interacting with 
VRC metabolism. The infection respondecl after increase of the VRC 
dose to 300 mg orally twice daily. (D) Patient with probable pulmonary 
aspergillosis and an uneventful clinical course. VRC concentrations 
were stable (è.AUC - 9.9%). The VRC dose was 300 mg twice claily, 
the route was i.v. on clays 2 and 7, and there was no comedication 
interacting with VRC metabolism. 
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separation followed by UV detection over 12 min were used 
for HPLC. The absolute recovery of VRC from plasma was 
close to 100%. The method has been validated according to 
international guidelines over the 0.25- to 16-mg/liter analytical 
range, which covers the clinically relevant concentration spec-
trum (5-7, 10, 14, 27, 35). Results are not influenced by type of 
organic matrix or anticoagulant and are reproducible under 
different storage conditions. The technique selectively detects 
VRC in the presence of a large number of frequently used 
antimicrobial and immunosuppressive drugs: analytical inter-
ferences have been observed only with the antiretroviral agents 
indinavir and amprenavir. Simple preanalytical processing and 
short analytical time (results available within 6 h) are advan-
tages of this HPLC technique over those previously reported. 
The new bioassay uses an azole-hypersusceptible C. albicans 
mutant constructed by targeted deletion of genes encoding 
multidrug etflux transporters and calcineurin subunit A (31). 
This simple test using very small volumes of plasma (50 µ!,i.e., 
10 times lower that those needed for HPLC) has an analytical 
range identical to that of HPLC (0.25 to 16 mg/liter). The 
concordance between VRC levels measured in clinical plasma 
samples by HPLC and bioassay was excellent. Despite a longer 
analytical time ( 16 h ), bioassay may be a valid alternative to 
HPLC. Bioassay is particularly useful for analyses with small 
volumes of blood ( e.g., from children), when analytical inter-
ferences alter detection of VRC by HPLC, or in laboratories 
not equipped for HPLC. 
Multiple factors have been associated with interindividual 
variations of VRC blood levels (10, 13, 16, 28, 37). Decrease of 
VRC blood levels during therapy has been reported in exper-
imental models with rats, mice, and dogs (30). Autoinduction 
of cytochrome P450 metabolism by VRC has been associated 
with this phenomenon. It is unclear whether intraindividual 
variations also occur in humans (10, 16, 28). The utility of 
measuring VRC blood levels to improve clinical management 
has been a matter of debate in recent reports (5-7, 10, 18, 27, 
33, 35). We sequentially measured VRC blood levels in 
Caucasian adult patients receiving standard doses of VRC for 
invasive mycoses. Large inter- and intraindividual variations of 
VRC blood levels were observed. During the study period, 
VRC exposure decreased or increased in 8 out of 10 patients 
despite the absence of changes in VRC doses and of comedi-
cations interacting with VRC metabolism or liver fonction. 
Although oral bioavailability of VRC is excellent, an intrave-
nous-to-oral switch might have intluenced VRC blood levels in 
some patients (10, 16, 28). Three clinical cases were illustrated. 
The first patient received esomeprazole as comedication and 
developed a toxic encephalopathy probably related to increas-
ing VRC exposure (Cmax level, 8.2 mg/liter; trough level, 7 
mg/liter; AUC, 93.1 mg · h/liter), which completely resolved 
after interruption of therapy. Rechallenge with lower doses of 
VRC was well tolerated. In a second neutropenic patient with 
persistent clinical and radiological signs of a probable invasive 
aspergillosis, a decrease in VRC blood levels and AUC (C111m 
level, 0.3 mg/liter; trough level, 0.2 mg/liter; AUC, 2.9 mg · 
h/liter) was observed. No cause of this drop in VRC exposure 
was identified. Infection responded after increase of the VRC 
dose. In a third leukemic patient, persistence of a possible 
pulmonary mycosis despite appropriate VRC blood levels re-
quired a switch to a salvage therapy. In the remaining seven 
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patients, the clinical course was uneventful. These prelimina1y 
observations suggest that, in addition to interindividual differ-
ences, important intraindividual variations of VRC blood lev-
els may occur during therapy. Small sample size and Jack of 
data on genetic polymorphism of CYP2C19 are important litn-
itations of this study. Nevertheless, in addition to those previ-
ously reported by other investigators, our clinical data suggest 
that VRC over- or underexposure might be associated with 
toxicity or persistence of infection, respectively. Simple, accu-
rate, and precise HPLC and bioassay techniques offer new 
tools for monitoring VRC therapy. 
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